A Potential New Use for Tocilizumab: Refractory Checkpoint Inhibitor Hepatitis

被引：2
|
作者：
Lyles, Laine [1 ]
Farmer, Reagan [2 ]
Abougergi, Marwan [3 ]
机构：
[1] Univ South Carolina, Prisma Hlth, Columbia, SC 29208 USA
[2] Univ South Carolina, Sch Med Columbia, Columbia, SC USA
[3] Catalyst Med Consulting, Simpsonville, SC USA
来源：
ACG CASE REPORTS JOURNAL | 2023年 / 10卷 / 09期
关键词：
autoimmune hepatitis; drug-induced autoimmune hepatitis; check point inhibitor; chemotherapy; renal cell carcinoma; hepatitis; drug induced liver injury; steroid refractory; tocilizumab; nivolumab; ipilimumab; CANCER;
D O I：
10.14309/crj.0000000000001162
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Immune checkpoint inhibitors are becoming more commonly used for many forms of malignancy. With this class of medications being more heavily used, there has been an associated rise in medication-induced autoimmune hepatitis. This case involves a 35-year-old woman being treated with nivolumab/ipilimumab for renal cell carcinoma who developed a steroid-refractory autoimmune hepatitis.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
    Pirker, I.
    Rubbert-Roth, A.
    von Kempis, J.
    Pehr, M.
    Neumann, T.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : 573 - 574
  • [22] A Case Report of Immune Checkpoint Inhibitor-Induced Aortitis Treated with Tocilizumab
    Bloomer, Chance H. H.
    Annabathula, Rahul V. V.
    Aggarwal, Vanya
    Upadhya, Bharathi
    Lycan, Thomas W. W.
    CASE REPORTS IN IMMUNOLOGY, 2022, 2022
  • [23] Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
    Hansen, Inga
    Koett, Julian
    Heidenreich, Silke
    Ayuk, Francis A.
    Doll, Patricia
    Abeck, Finn
    Booken, Nina
    Gebhardt, Christoffer
    Schneider, Stefan W.
    JEADV CLINICAL PRACTICE, 2024, 3 (01): : 317 - 320
  • [24] Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
    Abid, Muhammad Bilal
    Peck, Rachel
    Abid, Muhammad Abbas
    Al-Sakkaf, Wesam
    Zhang, Yuening
    Dunnill, Giles S.
    Staines, Konrad
    Sequeiros, Iara-Maria
    Lowry, Lisa
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 320 - 323
  • [25] Tocilizumab treatment for new onset refractory status epilepticus
    Jun, Jin-Sun
    Lee, Soon-Tae
    Kim, Ryul
    Chu, Kon
    Lee, Sang Kun
    ANNALS OF NEUROLOGY, 2018, 84 (06) : 940 - 945
  • [26] Pituitary Complications of Checkpoint Inhibitor Use
    Chamorro-Pareja, Natalia
    Faje, Alexander T.
    Miller, Karen K.
    ENDOCRINOLOGY, 2024, 165 (09)
  • [27] Enteritis with immune checkpoint inhibitor use
    Sanders, David
    Webber, Douglas
    Chatur, Nazira
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (40) : E1106 - E1106
  • [28] The Pesky Problem with Pembrolizumab: A Case of Chronic Hepatitis B Reactivation After Use of a Checkpoint Inhibitor
    Arnold, Casey
    Rivera, Kimberly
    Paul, Shira
    Bush, Allison
    Joya, Christie
    Roth, Michael
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2939 - S2939
  • [29] The role of the microbiome in immune checkpoint inhibitor colitis and hepatitis
    Ryan, Thomas
    Ling, Sophia
    Trinh, Andrew
    Segal, Jonathan P.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2024, 72
  • [30] Immune Checkpoint Inhibitor-Associated Colits and Hepatitis
    Reddy, Haritha G.
    Schneider, Bryan J.
    Tai, Andrew W.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2018, 9
12345